Vivos Therapeutics, Inc. (VVOS) Form 8-K — Sep 4, 2026
Vivos Therapeutics entered twelve separate exchange agreements with Streeterville Capital effective August 31, 2026, partitioning $2,861,270 of the outstanding Streeterville Note into twelve secured promissory notes that Streeterville will surrender in exchange for up to 11,445,080 common shares at an average exchange price of about $0.25 per share. The issuance will lift shares outstanding from 22,164,313 to 33,609,393, meaning the new shares equal roughly 52% of the pre-exchange share count and about 34% of the post-exchange total. After these exchanges, $3.7 million of Streeterville note principal remains outstanding.
Key figures
- Debt Amount
- $2,861,270 (partitioned note principal to be exchanged for equity)
- Offering Price
- $0.25 per share (average exchange price, at or above Nasdaq Minimum Price)
- Shares Offered
- 11445080
- Prior exchanges
- 785,822 shares for $975,000 of redemption obligations (Dec 2025–May 2026); $3,250,000 of principal exchanged Aug 4, 2026 for 2,500 Series B Non-Convertible Preferred shares plus 1,812,031 common shares
- Cash proceeds received
- 0
- Remaining note balance
- $3.7 million after the exchanges
- Original note principal
- $8,225,000 (Streeterville Note, issued June 9, 2025)
- Number of exchange agreements
- 12
- Beneficial ownership limitation
- 4.9%
- Shares outstanding pre exchange
- 22164313
- Exchange shares pct pre exchange
- approximately 52%
- Shares outstanding post exchange
- 33609393
- Exchange shares pct post exchange
- approximately 34%
Price after filing
Close on the filing date to close N calendar days later (from $0.19). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.